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Eukaryotic cells coordinately control anabolic and catabolic processes to maintain cell and tissue homeostasis. Mechanistic target of rapamycin complex 1 (mTORC1) promotes nutrient-consuming anabolic processes, such as protein synthesis 1 . Here we show that as well as increasing protein synthesis, mTORC1 activation in mouse and human cells also promotes an increased capacity for protein degradation. Cells with activated mTORC1 exhibited elevated levels of intact and active proteasomes through a global increase in the expression of genes encoding proteasome subunits. The increase in proteasome gene expression, cellular proteasome content, and rates of protein turnover downstream of mTORC1 were all dependent on induction of the transcription factor nuclear factor erythroid-derived 2-related factor 1 (NRF1; also known as NFE2L1). Genetic activation of mTORC1 through loss of the tuberous sclerosis complex tumour suppressors, TSC1 or TSC2, or physiological activation of mTORC1 in response to growth factors or feeding resulted in increased NRF1 expression in cells and tissues. We find that this NRF1-dependent elevation in proteasome levels serves to increase the intracellular pool of amino acids, which thereby influences rates of new protein synthesis. Therefore, mTORC1 signalling increases the efficiency of proteasome-mediated protein degradation for both quality control and as a mechanism to supply substrate for sustained protein synthesis.
In response to growth signals, mTORC1 promotes anabolic processes, such as protein synthesis, and its chronic activation is believed to underlie a variety of complex human diseases, including cancer and metabolic diseases, as well as pathologies associated with ageing 1, 2 . Cells must possess mechanisms to coordinate protein synthesis with protein turnover to maintain amino acid and protein homeostasis, as even a small persistent imbalance between these processes can disrupt cell and tissue physiology 3, 4 . Given the ubiquitous role of mTORC1 in stimulating protein synthesis, we sought to assess the effects of mTORC1 activation on protein degradation.
A protein complex comprising TSC1, TSC2 and TBC1D7 (the TSC complex) serves as a central negative regulator of mTORC1, with loss of its components resulting in growth-factor-independent activation of mTORC1 (ref. 1). Tsc2 2/2 mouse embryonic fibroblasts (MEFs) exhibit growth-factor-independent activation of mTORC1, as scored by phosphorylation of S6K1 and S6 (Extended Data Fig. 1a ), which is blocked by the mTORC1 inhibitor rapamycin or reconstitution with human TSC2. Both TSC1-and TSC2-deficient MEFs displayed a 20-25% increase in the rate of de novo protein synthesis, which was abolished by rapamycin ( Fig. 1a and Extended Data Fig. 1b) . To analyse relative turnover rates of newly synthesized proteins, the percentage of total labelled protein remaining over time was measured in a pulse-chase experiment (Extended Data Fig. 1c ). Both TSC1-and TSC2-deficient cells displayed a rapamycin-sensitive increase in the rate of protein degradation (Fig. 1b and Extended Data Fig. 1d-f ). This was surprising given the well-established role of mTORC1 in inhibiting autophagy, a lysosome-dependent mechanism of degrading organelles and proteins 5 . While the lysosome inhibitor chloroquine slowed the rate of protein degradation, cells lacking TSC2 maintained a rapamycin-sensitive increase in protein turnover, and rapamycin also slowed rates of protein degradation in autophagydeficient (Atg7 (20 min) . Data are mean 6 standard error of the mean (s.e.m.) (n 5 3). **P , 0.01, {P , 0.05. b, Cells treated as in a were pulse labelled for 30 min and chased in medium containing vehicle or rapamycin. The rate of protein degradation is shown as the fraction of radiolabelled protein remaining over time. c, d, Cells were treated as in b, except that 10 mM chloroquine (c) or 0.02 mM bortezomib (d) was present in the chase media. b-d, Data are mean 6 s.e.m. (n 5 3; note: small error bars are masked by line symbols). *P , 0.05, **P , 0.01, at 48 h. e, The cells from a were serum starved for 16 h with vehicle (Veh) or 20 nM rapamycin, or treated for 2 h with MG132 (MG; 0.1 mM) or bortezomib (Bort; 0.2 mM). Proteasome activity is presented as mean 6 s.e.m. relative to vehicletreated cells expressing TSC2 (n 5 3). *P , 0.05, {{P , 0.01. f, Cells were serum starved for 24 h with vehicle (V), 20 nM rapamycin (R) or 2.5 mM PP242 (P). Intact proteasome levels are presented as mean 6 s.e.m. relative to vehicletreated TSC2-expressing cells (n 5 3). Graphs are labelled as in e; *P , 0.05, {P , 0.05, {{P , 0.01. a-e, Statistical significance for pairwise comparisons evaluated with a two-tailed Student's t-test.
A role for the proteasome as the other major cellular mechanism of proteolysis was examined. As with rapamycin, two structurally distinct proteasome inhibitors, bortezomib and MG132, blocked the enhanced rate of protein degradation in TSC2-deficient cells ( Fig. 1d and Extended Data Fig. 2d-f ). TSC2-deficient cells possessed significantly higher proteasome activity relative to TSC2-expressing cells, which was attenuated by rapamycin and abolished with proteasome inhibitors (Fig. 1e) . The levels of intact proteasomes were measured in four distinct isogenic pairs of cells, including Tsc2 2/2 MEFs and a TSC2 2/2 human angiomyolipomaderived cell line expressing either empty vector or human TSC2, and HeLa and MCF10A cells stably expressing control or TSC2-targeting short hairpin (sh)RNAs. TSC2 loss and mTORC1 activation resulted in a significant increase in cellular proteasome content in all four lines, which was reversed by rapamycin or the mTOR kinase inhibitor PP242 ( Fig. 1f and Extended Data Fig. 2g, h) .
To determine the mechanism of proteasome increase downstream of mTORC1, we focused on transcriptional regulation, as induced expression of the genes encoding proteasome (PSM) subunits has been established as a major mechanism controlling cellular proteasome content 7, 8 . Interestingly, in a previous transcriptional profiling study, gene set enrichment analysis of mTORC1-induced transcripts found that the most enriched gene set was 'Parkin disorder under Parkinson disease' 9 . In examining the genes driving this enrichment score, we found that ten PSM genes scored as being significantly stimulated by mTORC1 (Extended Data Fig. 3a) . We confirmed that mTORC1 activation induced the expression of messenger RNAs encoding subunits of both the 20S core and 19S regulatory complex of the proteasome in two independent sets of Tsc2-null MEFs and in HeLa cells with stable knockdown of TSC2, as well as wild-type MEFs stimulated with serum ( Fig. 2a and Extended Data Fig. 3b-e) . NRF1 has been demonstrated to induce the global expression of PSM genes through direct binding of shared regulatory elements in their promoters 7, 8 . Importantly, short interfering (si)RNA knockdown of NRF1, but not the closely related NRF2 (also known as NFE2L2), blocked the mTORC1-dependent induction of PSM genes and led to a decrease in intact proteasome levels in multiple TSC2-deficient cell lines (Fig. 2b, c and Extended Data Fig. 4a-d) . Reciprocally, exogenous overexpression of two different Nrf1 complementary DNA constructs led to elevated levels of intact proteasomes, which, unlike control cells, were resistant to the effects of rapamycin ( Fig. 2d and Extended Data Fig. 4e ). Like rapamycin, NRF1 knockdown blocked the enhanced rate of protein turnover in TSC2-deficient cells ( Fig. 2e and Extended Data Fig. 4f, g ). Collectively, these data indicate that NRF1 functions downstream of mTORC1 in promoting proteasome-mediated protein degradation.
A rapamycin-sensitive increase in NRF1, but not in NRF2, protein levels was observed in multiple mouse and human cell lines lacking TSC2, as well as in HEK293 cells overexpressing RHEB, the downstream target of the TSC complex that activates mTORC1 (Fig. 2b and Extended Data Figs 4b, c, f and 5a-c) 1 . In wild-type cells, mTORC1 signalling is dependent on growth factors, and NRF1, but not NRF2, was upregulated in a rapamycin-sensitive manner over a time course of growth factor stimulation (serum, epidermal growth factor (EGF) or insulin) in wildtype MEFs, MCF10A and HeLa cells (Fig. 3a and Extended Data Fig. 5b, c) . The mTORC1-mediated induction of NRF1, through either growth factors or TSC2 loss, was reflected in an increase in both the unprocessed (p120) and processed (p110) isoforms of NRF1 (ref. 10) , as seen most clearly on a NuPage gradient gel (Extended Data Fig. 5d ). Rapamycin also decreased the protein levels of individual proteasome subunits, as well as an insulin-stimulated increase in intact 26S proteasomes (Extended Data Fig. 5e, f) .
Chronic mTORC1 signalling can cause endoplasmic reticulum (ER) stress and activate the unfolded protein response (UPR) 11 , an adaptive response that includes increased proteasomal degradation of ER proteins 12 . Indeed, TSC2-deficient cells displayed a rapamycin-sensitive increase in phosphorylation of the UPR effector PERK (also known as EIF2AK3) (Extended Data Fig. 6a ). However, classical chemical inducers of ER stress, tunicamycin and thapsigargin, failed to induce NRF1 in wild-type cells. Consistent with previous studies 7, 8 , treatment of cells with proteasome inhibitors led to increased NRF1 protein levels, comparable to those seen in TSC2-deficient cells. However, in contrast to TSC2 depletion, 
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RHEB overexpression and growth factor stimulation, the proteasomeinhibitor-induced increase in NRF1 levels was not reversed by rapamycin. Therefore, mTORC1 signalling increases NRF1 levels in a manner that is independent of both the UPR and the proteasome recovery pathway. Finally, we failed to detect effects of mTORC1 on the nuclear and cytosolic distribution of NRF1 (Extended Data Fig. 6b, c) .
The timing of NRF1 induction upon mTORC1 activation (6 to 12 h), and the fact that expression of NRF1 from an exogenous promoter led to elevated levels of NRF1 and proteasomes that were no longer sensitive to rapamycin, suggested that mTORC1 might regulate NRF1 through transcriptional control mechanisms. Indeed, Nrf1 transcript levels were elevated and sensitive to mTOR inhibitors in Tsc2-null cells (Fig. 3b) . Amongst the transcription factors identified to be downstream of mTORC1 (ref. 9) , we found that the sterol regulatory element binding protein 1 (SREBP1; also known as SREBF1) regulated Nrf1 gene expression. siRNAmediated knockdown of SREBP1, but not SREBP2, decreased Nrf1 transcript levels to a similar extent as rapamycin in both TSC2-deficient MEFs ( Fig. 3c ) and human angiomyolipoma-derived cells (Extended Data Fig. 7a ), and SREBP1 depletion also decreased NRF1 protein levels (Fig. 3d) . Reciprocally, exogenous expression of mature, active SREBP1c upregulated NRF1 and rendered its expression resistant to rapamycin (Fig. 3e) . Analysis of previous genomic data sets from studies aimed at identifying targets of SREBP1, including genome-wide expression 13 and chromatin immunoprecipitation (ChIP) 14 , further suggested that the NRF1 gene is directly regulated by SREBP1. Bioinformatic analysis of the human and rodent NRF1 loci identified four consensus and conserved sterol regulatory elements in proximity with the two predicted transcription start sites (Extended Data Fig. 7b) . A ChIP assay demonstrated that mature SREBP1c bound to the NRF1 promoter, where Pol II binding was also enriched (Fig. 3f) . As controls, SREBP1c also bound to the promoter of its established target SCD but not to the promoters of GAPDH or NRF2 (Extended Data Fig. 7c ). As mTORC1 signalling increases the accumulation of active SREBP1 (ref. 9), these collective findings indicate that SREBP1 lies downstream of mTORC1 in the induction of NRF1 expression.
We next examined mouse models of both genetic and physiological activation of mTORC1 signalling in the brain and liver, respectively. A brain model of tuberous sclerosis complex involving a conditional hypomorphic allele of Tsc2 (Tsc2
) was used, in which exon 3 is deleted in neurons through Cre expression from the synapsin I promoter (Syn1-cre) 15 . Brain lysates from Tsc2
;Syn1-cre (neuron-specific deletion) mice were compared. This allelic series showed a graded loss of TSC2 protein with a corresponding increase in mTORC1 signalling, elevated NRF1 protein and mRNA levels, with no change in Nrf2 expression, and a corresponding increase in PSM transcript and protein levels (Fig. 4a-c and Extended Data Fig. 8a ). NRF1 has been shown to control PSM gene expression in hepatocytes 16 . mTORC1 signalling is strongly activated in the liver upon feeding 17 . This stimulation was associated with an increase in the protein and mRNA levels of NRF1, but not NRF2, as well as representative PSM transcripts, and these were blocked with a single dose of rapamycin just before feeding (Fig. 4d, e and Extended Data Fig. 8b ). These data provide in vivo support for NRF1 activation and proteasome induction downstream of mTORC1 signalling.
We hypothesized that, in addition to serving as a quality control mechanism for newly translated proteins, the enhanced proteasome activity upon mTORC1 activation could serve to maintain adequate pools of amino acids to sustain new protein synthesis. Indeed, while inhibition of translation with rapamycin or cycloheximide increased amino acids, proteasome inhibitors significantly depleted intracellular amino acids ( Fig. 4f and Extended Data Fig. 9a ). Likewise, two distinct siRNAs targeting NRF1 elicited a significant decrease in intracellular amino acids, similar to bortezomib treatment ( Fig. 4f and Extended Data Fig. 9b ). Depletion of intracellular amino acids upon Nrf1 knockdown or bortezomib treatment was also reflected in a decreased rate of protein synthesis, which was much more pronounced under conditions of lower exogenous amino acids (Fig. 4g, h and Extended Data Fig. 9c, d) . However, the differences in protein synthesis under low and high amino acid conditions were not reflected in differences in mTORC1 signalling (Extended Data Fig. 9e ). Finally, TSC2-deficient MEFs and MCF10A cells exhibited increased sensitivity to NRF1 knockdown (Extended Data  Fig. 10a, b) , indicating the importance of NRF1 induction for viability in the context of mTORC1 activation. Collectively, our findings suggest a model whereby the mTORC1-stimulated expression of NRF1 and subsequent increase in cellular proteasome activity serve as a delayed, but pre-programmed, adaptive response accompanying increased protein synthesis downstream of mTORC1 (Extended Data Fig. 10c ). 
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Relative expression S-methionine, cell labelling grade, was obtained from PerkinElmer Life Sciences; L-methionine, chloroquine, MG132, tunicamycin, thapsigargin, cycloheximide, trichloroacetic acid, sodium salicylate, protease inhibitor cocktail, DMEM/F12, insulin, hydrocortisone, cholera toxin and fetal bovine serum from Sigma; methionine-free DMEM, Basal Medium Eagle (BME), 50X amino acids solution, horse serum, transfection reagents Lipofectamine 2000 and Lipofectamine RNAiMAX, and NuPAGE Novex 4-12% Bis-Tris protein gel from Life Technologies Corporation; rapamycin and bortezomib from LC Laboratories; torin 1 and PP242 from Tocris; EGF from Peprotech. DNA constructs. The following plasmids were used. pcDNA3.1, pcDNA3.1-23 Flag-SREBP1c (Addgene plasmid 26802) 18 and pShuttle-CMV (Addgene plasmid 16403) 19 . A pCMV-Sport6 vector encoding the mouse Nrf1 cDNA (GenBank accession BC047283.1) was acquired from Open Biosystems (ThermoScientific). The Nrf1 cDNA was PCR amplified with the addition of tag elements incorporated onto its 59 (His) or 39 (Flag or Myc) ends, along with suitable restriction sites, which were then used to subclone into the pShuttle-CMV vector. Cell lines. MEF, HeLa and HEK293 lines were maintained in DMEM with 4.5 g l 21 glucose containing 10% fetal bovine serum and were mycoplasma free. The isogenic pair of Tsc2 2/2 MEFs reconstituted with human TSC2 or empty vector were described previously 20 . ) and Tsc1 1/1 and Tsc1 2/2 MEFs were described previously 21, 22 . The TSC2-null human cell line derived from a renal angiomyolipoma 23 expressing either empty vector or human TSC2 was a gift from E. P. Henske. The HeLa cell line stably expressing control shRNAs or those targeting TSC2 was also previously described 20 . The MCF10A cell line stably expressing control shRNAs or those targeting TSC2 was maintained in DMEM/F12 containing 5% horse serum, human EGF (20 ng ml 21 ), hydrocortisone (0.5 mg ml 21 ), cholera toxin (100 ng ml 21 ), insulin (10 mg ml
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) and puromycin (0.5 mg ml
) for selection purpose. To generate HEK293 cells stably expressing the tagged NRF1 constructs, the pShuttle-CMV construct encoding NRF1 was transfected into HEK293 cells, which then underwent G418 (500 mg ml Mice. The neuron-specific Tsc2 hypomorphic mutant mice used in this study were described previously 15 . Two mice of each genotype were used for this qualitative analysis. Immediately following euthanasia, brains were harvested and sections of frontal cortex were flash-frozen in liquid nitrogen. Total time between euthanasia and freezing was kept below 5 min for all samples. For fasting-refeeding studies in wild-type mice, the experimental procedure was detailed previously 17 . Briefly, twelve 8-week-old C57BL/6J male mice were fasted overnight and either euthanized (n 5 4) or refed normal chow for 6 h (n 5 8). Vehicle (5% Tween-80, 5% PEG-400 in PBS; n 5 4) or rapamycin (10 mg kg
; n 1 4) was administered via intraperitoneal (i.p.) injection 30 min before refeeding. These experiments were performed in an unblinded fashion. Procedures were carried out in accordance with the Guide for the Humane Use and Care of Laboratory Animals, and the research protocol was approved by the Animal Care and Use Committees of Boston Children's Hospital and Harvard Medical School. Protein synthesis and degradation with metabolic radiolabelling. Cells were serum starved for 16 h in the presence of vehicle (dimethylsulphoxide (DMSO)) or 20 nM rapamycin in 6-well plate. To assess protein synthesis, cells were starved for 30 min with methionine-free DMEM and radiolabelled for 20 to 30 min with 35 SMet before lysis and SDS-PAGE. To compare the effects of exogenous amino acid levels (Fig. 4h) , 16 h before radiolabelling, cells were switched to either BME media, which contains physiological concentrations of amino acids (low amino acid), or BME media supplemented with amino acids to a final concentration that is eightfold higher, which is equal to twice that of DMEM (high amino acid). To assess protein degradation, cells were starved for 30 min with methionine-free DMEM and pulselabelled for 30 min with 0.5 ml of medium containing 0.1 mCi of 35 S-Met. Cells were then washed with Met-free DMEM and chased for various periods in DMEM containing 1 mM Met. After washing in cold PBS, lysis was conducted in 200 ml of RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% sodium deoxycholate, 0.1% SDS, 1% NP-40, 150 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 10 mM glycerol 2-phosphate, 50 mM NaF, 0.5 mM sodium orthovanadate and protease inhibitor cocktail). Following centrifugation at 10,000g, supernatants were boiled with SDS sample buffer and analysed by SDS-PAGE (10% gel) followed by fluorography. The entire lane of each sample was quantified using ImageJ (National Institutes of Health) on scanned films. Backgrounds were subtracted by quantifying a blank area of the film corresponding in size to that of the gel lane of interest, and the results were normalized to cell numbers in a parallel set of cells with the same treatment. The graphed data were quantified from three independent experiments performed on separate occasions, with representative films from one such experiment per condition also provided in Extended Data Figs 1d, f, 2a, c, d, f, 4g and 9c, d) .
Immunoblotting. Cells were lysed in an NP-40 lysis buffer (40 mM HEPES, pH 7.4, 120 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, 10 mM sodium pyrophosphate, 10 mM glycerol 2-phosphate, 50 mM NaF, 0.5 mM sodium orthovanadate and protease inhibitors) or, in experiments where transcription factors were to be detected, RIPA buffer. For animal studies, freshly resected tissues, snap-frozen in liquid nitrogen, were homogenized in NP-40 lysis buffer containing 1 mM dithiothreitol (DTT). Tissue or cell debris was cleared by subsequent 30 min centrifugations at 16,000 r.p.m. Normalized protein lysates were separated by SDS-PAGE, transferred onto an Immobilon-P membrane (Millipore), subjected to immunoblotting with the given antibodies, and detected by ECL (Amersham Biosciences). The immunoblots in Extended Data Fig. 5d are from lysates run on a 4-12% continuous gradient NuPAGE gel. Proteasome activity assay. Cells were serum starved for 16 h in the presence of vehicle (DMSO) or 20 nM rapamycin, or treated for the final 2 h with MG132 (0.1 mM) or bortezomib (0.2 mM). Proteasome activities were measured in cell lysates. The fluorogenic substrate Suc-LLVY-AMC (Promega, G8660) was used to measure the chymotrypsin-like proteasome activity in both 20S and 26S proteasomes. Assays were carried out in a 200 ml reaction volume according to the manufacturer's instructions. Proteasome activity was determined as the rate of cleavage of the fluorescent substrate over 10 min and activity was expressed as arbitrary fluorescence units after normalizing to the total protein concentration. Fluorescence was measured on a BioTek Synergy 2 Multi-Mode Microplate Reader (BioTek Instruments) at excitation and emission wavelengths of 380 nm and 460 nm, respectively. Proteasome quantification assay. Two distinct ELISA kits were used for mouse and human proteasome quantification, with the mouse version being specific for the 26S proteasome and the human version being specific for the 20S proteasome. To determine 20S proteasome concentrations in human cell lysates, we used a proteasome ELISA kit according to the manufacturer's instructions (BML-PW0575, Enzo Life Sciences). Briefly, cells were lysed at a concentration of approximately 1 3 10 7 cells ml
. Cell lysates were diluted 1:100, and 100 ml of the diluted lysates were incubated for 1 h at room temperature in 96-well plates pre-coated with the anti-proteasome antibody. Standard curves for quantification were established, using purified proteasomes in a concentration range from 0 to 1.6 mg ml 21 . After washing, 100 ml detection antibody was added and incubated for 1 h at room temperature. Wells were washed again and bound antibodies were detected after labelling with secondary antibody. The plates were washed and read at 450 nm after 10 min of incubation with substrate solution. The 26S proteasome concentration in MEFs was determined by a mouse 26S proteasome ELISA kit (E03A0669, BlueGene Biotech), following the manufacturer's protocol. The procedure was the same as that described earlier except that cells were lysed by freeze-thaw cycles and cell lysates were diluted 1:10. qRT-PCR. For gene expression analyses, RNA was isolated from cultured cells using the RNeasy Mini Kit (Qiagen) and from mouse tissue using TRIzol (Life Technologies Corporation), according to the manufacturers' instructions. cDNA was prepared using the Superscript III First-Strand Synthesis System for RT-PCR kit (Life Technologies Corporation). Transcript abundance was determined using SYBR Green PCR mix (Applied Biosystems) and primers specific for each transcript. qRT-PCR was performed using an Applied Biosystems 7300 Real-Time PCR System. Triplicate samples were collected for each experimental condition, and measurements were then normalized to Rplp0 (m36b4) mRNA to determine relative expression levels. Oligonucleotides used for qPCR of mouse mRNAs are as follows. Psma1:
RESEARCH LETTER elements for SREBP1 in the promoter region of the NRF1 genes from human and rodents, a python script that uses the Biopython package to search for sterol regulatory elements in a given promoter was created. ENTREZ was used to acquire the promoter sequence of human, mouse and rat NRF1 from PubMed, and the motif module was used to look for sterol regulatory elements 24 . The motif search was based on a position weight matrix from 20 established SREBP targets developed previously 25 . The visual representation of the sterol regulatory element position weight matrix, and its reverse complement, were created using WebLogo 26 . The promoter sequences were aligned using the ClustalX program 27 in order to identify the conserved motifs. ChIP. HEK293 cells were transfected with Flag-tagged active SREBP1c or empty vector, followed by 7 days of selection in G418. ChIP assays were performed using a ChIP kit (Thermo Scientific) according to the manufacturer's instructions with minor modifications. Briefly, cells were fixed with 1% formaldehyde for 10 min at room temperature to crosslink existing protein-DNA interactions. The fixed cells were harvested and lysed in the provided lysis buffer with protease inhibitors added. The nuclei were collected by centrifugation, and chromatin was sheared to fragments of 400-1,000 bp using micrococcal nuclease (37 uC, 30 min). Nuclei were resuspended in nuclear lysis buffer containing phosphatase and protease inhibitors and debris was removed by centrifugation. Ten per cent of the chromatin was kept as input and the remaining was diluted tenfold with dilution buffer. Immunoprecipitation was performed with antibodies against the Flag epitope, RNA polymerase II, or nonspecific control IgG overnight at 4 uC. The IgG-protein-DNA complexes were captured with protein A/G agarose for 1 h and the beads were washed. Bound DNA was eluted with elution buffer and, along with the input DNA, was subjected to reverse crosslinking at 65 uC for 2 h with shaking. Following proteinase K treatment, DNA was recovered using the DNA Clean-Up Column and was subjected to qRT-PCR with specific primers for different promoter regions. Primers against the SCD and GAPDH promoters served as positive and negative controls, respectively. The relative occupancy of SREBP1c at the given locus was calculated by sequential normalization to the input and to the DNA present in immunoprecipitations with control IgG. Primer sequences used for qRT-PCR of promoter regions of human genes are as follows. NRF1 #1: forward 59-GGCTGTTGTCAGGGATAGGA-39, reverse 59-AGAAGCCCCTCACAGACTCA-39; NRF1 #2: forward 59-AACGTG GCCATATCCTTCTG-39, reverse 59-GGGCAACAAGAGCAAAACTC-39; NRF1 #3: forward 59-ACATGGCAAAACCCTGTCTC-39, reverse 59-AGATGGAGTC GCTCTGTGGT-39; SCD: forward 59-CTCAGGAAACAGTGGTGAACCC-39, reverse 59-GCAGAGCCATTGTTCGCAGG-39; GAPDH: forward 59-TACTAG CGGTTTTACGGGCG-39, reverse 59-TCGAACAGGAGGAGCAGAGAGCGA -39; NRF2: forward 59-GAAGGTCTGGGGACTGAGC-39, reverse 59-CCCGTG ACTAGGCACATTTT-39. Measuring intracellular amino acid levels. Cells were serum starved for 16 h and treated for 1 h with the specified compounds in 96-well plates. Amino acid levels were quantified in triplicate using an L-Amino Acid Assay Kit (Abcam) following the manufacturer's instructions. Briefly, cells were washed with PBS and lysed in an Assay Buffer. A standard curve for quantification was established, using L-Amino Acid Standards in a concentration range from 0 to 80 nmol ml 21 . Fifty microlitres of the Reaction Mix was added to each well containing the L-Amino Acid standard or test samples and the reaction was incubated for 30 min at 37 uC. The L-amino acid levels were quantified using fluorometric analysis on a BioTek Synergy 2 MultiMode Microplate Reader (BioTek Instruments) at excitation and emission wavelengths of 535 nm and 590 nm, respectively, and were normalized to cell numbers in parallel wells. Subcellular fractionation. Cells were serum starved for 24 h in the presence of vehicle or rapamycin and nuclear/cytoplasmic fractionation was performed using the Nuclear Extract Kit (Active Motif) as per the manufacturer's instructions. In brief, cells were collected, resuspended in Hypotonic Buffer, and incubated on ice for 15 min. Cells were lysed and the nuclei were pelleted by centrifugation, with the supernatant corresponding to the cytoplasmic fraction. To isolate nuclear proteins, the nuclei were lysed in Complete Lysis Buffer and the debris was removed by centrifugation. Viable cell counts. TSC2-expressing or deficient MEFs (TSC2 addback or vector) or MCF10As (control or TSC2 shRNAs) were transfected with siRNAs targeting NRF1 or non-targeting control siRNAs. At 48 h post-transfection, 1 3 10 5 cells were reseeded per well in 6-well plates and grown in serum-free DMEM for 24 h. Triplicate samples were counted using trypan blue exclusion, and the mean viable cell numbers 6 s.e.m. for a representative experiment (n 5 2) are shown. Statistical analyses. Statistical analysis was used to support the main conclusions in this study. Unless otherwise specified, all experiments were performed at least three times. The sample size for each experiment is provided in the relevant figure legends and/or earlier, and unless otherwise specified, represents biological replicates/independent experiments performed on different days, each with technical triplicates. All values were reported as mean 6 s.e.m. Statistical significance for all pairwise comparisons was evaluated with a two-tailed Student's t-test, and a P value # 0.05 was considered significant. To our knowledge and observation, all of the biochemical measurements made provide data that is of a normal distribution and there is a similar variance among the groups. MEFs were used. Data are shown as the mean 6 s.e.m. (n 5 3). *P , 0.05 or **P , 0.01; {{P , 0.01 or {{{P , 0.001. c, MEF cell lysates obtained from the experiment in Fig. 2c were subjected to immunoblotting. d, The same experiment in Fig. 2c was performed, except HeLa cells expressing nontargeting shRNAs (shLUC) or shRNAs targeting human TSC2 (shTSC2) were used. Data are presented as mean 6 s.e.m. relative to vehicle-treated shLUCexpressing cells (n 5 3). *P , 0.05, {P , 0.05. e, f, Cell lysates obtained from the experiment in Fig. 2d and e, respectively, were subjected to immunoblotting. g, Autoradiograph of gel, representative of three independent experiments, corresponding to the data graphically represented in Fig. 2e . a, b, d, Statistical significance for pairwise comparisons was evaluated with a two-tailed Student's t-test. Fig. 3a , with just the starved and 24-h-stimulated samples, along with the vector-expressing Tsc2-null cells, were run on a 4-12% continuous gradient NuPAGE gel, followed by immunoblotting. e, Lysates from the insulin-stimulated cells obtained in Fig. 3a were subjected to additional immunoblotting. f, Tsc2-null MEFs reconstituted with wild-type TSC2 were stimulated with insulin (100 nM for 24 h), and intact proteasome levels were measured by enzyme-linked immunosorbent assay (ELISA) and are presented as the mean 6 s.e.m. (n 5 3). **P , 0.01, {{P , 0.01. f, Statistical significance for pairwise comparisons was evaluated with a two-tailed Student's t-test.
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